Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on oncedaily lamotrigine

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 337-342

  Steinbaugh, Linda ^a   Szaflarski, Jerzy P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Generalized seizures; GTC; IGE; Lamotrigine; Treatment

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PLACEBO; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ANTICONVULSANT THERAPY; ATAXIA; BLURRED VISION; COMBINATION CHEMOTHERAPY; DIPLOPIA; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENERALIZED EPILEPSY; HEADACHE; HUMAN; IDIOPATHIC DISEASE; MONOTHERAPY; MYOCLONUS EPILEPSY; REVIEW; RHINITIS; SOMNOLENCE; TONIC CLONIC SEIZURE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; ADULT; CHILD; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; GRAND MAL EPILEPSY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE;

ADULT; ANTICONVULSANTS; CHILD; DELAYED-ACTION PREPARATIONS; EPILEPSY, TONIC-CLONIC; HUMANS; MEDICATION ADHERENCE; TRIAZINES;

EID: 79952457600     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S11175     Document Type: Review

References (46)

1. Bai X, Vestal M, Berman R, et al. Dynamic time course of typical childhood absence seizures: EEG, behavior, and functional magnetic resonance imaging. J Neurosci. 2010;30:5884-5893.
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676-685.
3. Szaflarski JP, DiFrancesco M, Hirschauer T, et al. Cortical and subcortical contributions to absence seizure onset examined with EEG/fMRI. Epilepsy Behav. 2010;18:404-413.
4. Engel J Jr. Report of the ILAE classification core group. Epilepsia. 2006;47:1558-1568.
5. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: Expert opinion. Epilepsy Behav. 2005;7 Suppl 1:S1-S64.
6. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. Placebocontrolled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69:1751-1760.
7. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann- Delgado J. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70: 607-616.
8. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia. 2005;46 Suppl 9: 161-168.
9. Ng M, Devinsky O. Vagus nerve stimulation for refractory idiopathic generalised epilepsy. Seizure. 2004;13:176-178.
10. Szaflarski JP. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav. 2004;5:1024-1026.
11. Szaflarski JP, Lindsell CJ, Zakaria T, Banks C, Privitera MD. Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication response. Epilepsy Behav. 2010;17: 525-530.
12. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27:490-497.
13. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse. 1996;24:248-255.
14. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia. 2008;49:888-897.
15. Werz MA. Pharmacotherapeutics of epilepsy: Use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag. 2008;4:1035-1046.
16. Rheims S, Ryvlin P. Once-daily lamotrigine extended release for epilepsy management. Expert Rev Neurother. 2009;9:167-173.
17. Tompson DJ, Ali I, Oliver-Willwong R, et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediaterelease to a once-daily extended- release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia. 2008;49:410-417.
18. Kustra R, Tompson D, Job S, van Landingham K. A summary of the pharmacokinetic characteristics of lamotrigine extended-release tablets. Epilepsia. 2007;48:371.
19. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos. 2006;34:1055-1062.
20. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
21. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338-342.
22. Kustra RP, Tompson D, Wright J, Messenheimer J. Modeling and simulation of the phamacokinetics of once daily lamotrigine extended release to support the evaluation of dosing scenarios and comparisons with twice daily immediate-release lamotrigine. Epilepsia. 2008;49:439.
23. Vuong A, Hammer AE, Kerls SP, Caldwell PT, Messenheimer JA. Long term safety data with lamotrigine extended-release: A meta-analysis of 3 controlled clinical trials. Epilepsia. 2009;50:413.
24. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebocontrolled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia. 1998;39:1329-1333.
25. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology. 2005;65:1737-1743.
26. French J, Temkin N, Hammer A, van Landingham K. Time to the nth seizure analysis of lamotrigine as adjunctive therapy in subjects with primary generalized epilepsy. Epilepsia. 2007;48 Suppl 6:77-78.
27. Biton V, Vuong A, Kerls SP, Hammer AE, Messenheimer J. Onset of efficacy with lamotrigine in primary generalized tonic-clonic seizures (PGTC): A randomized, placebo controlled study. Epilepsia. 2005; 46 Suppl 8:206.
28. Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics. 2006;118: e371-e378.
29. Hammer A, Vuong A, Kerls S, Caldwell P, Messenheimer J. Pragmatic intent-to-treat analysis for lamotrigine extended-release from 3 epilepsy clinical trials. Epilepsia. 2009;413-414.
30. Biton V, Vuong A, Hammer A, Adams BE, Kerls S, Messenheimer J. Preliminary results with once-daily lamotrigine extended-release as adjunctive therapy in patients with primary generalized tonic-clonic seizures. In: 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, 2008 Apr 12-19.
31. Steinhoff BJ, Ueberall MA, Siemes H, et al; The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure. 2005;14:597-605.
32. Steinhoff BJ, Ueberall MA, Siemes H, Kurlemann G, Schmitz B, Bergmann L. The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure. 2005;14:597-605.
33. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial. Lancet. 2007;369:1016-1026.
34. Gericke CA, Picard F, de Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: A video-EEG-controlled, open study. Epileptic Disord. 1999;1:159-165.
35. Mazurkiewicz-Beldzinska M, Szmuda M, Matheisel A. Longterm efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents. Seizure. 2010;19:195-197.
36. Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology. 2005;65:762-764.
37. Maiga Y, Nogues B, Guillon B. [Exacerbation of tonicoclonic seizures in a juvenile myoclonic epileptic taking lamotrigine]. [in French] Rev Neurol (Paris). 2006;162:1125-1127.
38. Schimschock JR, Hammer AE, Kustra RP, Messenheimer JA. Effects of lamotrigine monotherapy in patients with newly diagnosed juvenile myoclonic epilepsy: An open-label study. Curr Ther Res Clin Exp 2005;66:230-237.
39. Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: Results of an open-label study. Epilepsy Behav. 2004;5:509-512.
40. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol. 2000;23:160-163.
41. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure. 1996;5:149-151.
42. Fallah R, Islami Z, Tavakoli N. Efficacy and safety of lamotrigine in refractory epilepsy of children. East J Med. 2008;13:7-12.
43. Timmings P, Richens A. Efficacy of lamotrigine as monotherapy for juvenile myoclonic epilepsy: Pilot study results. Epilepsia. 1993;34:160.
44. Garcia-Escriva A, Lopez-Hernandez N, Alvarez-Sauco M, et al. [Lamotrigine in refractory epilepsy]. Rev Neurol. 2004;38:301-303. Spanish.
45. Meo R, Bilo L, Mariniello A, et al. Lamotrigine as add-on therapy in drug resistant generalized epilepsies: Efficacy and tolerability. Lega Italiana contro l'Epilessia. 1999;106-107:309-311.
46. Szaflarski JP, Szaflarski M. Seizure disorders, depression, and healthrelated quality of life. Epilepsy Behav. 2004;5:50-57.